U.S. Point of Care Infectious Disease Testing Market (By Disease: Pneumonia Or Streptococcus Associated Infections, Respiratory Syncytial Virus (RSV), TB and Drug Resistant TB POC, Influenza/Flu POC, HIV POC, Others; By End-user: Hospitals, Clinics, Home, Assisted Living Healthcare Facilities, Laboratories, Others) - Regional Outlook and Forecast 2024 to 2033
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: U.S. Point of Care Infectious Disease Testing Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. U.S. Point of Care Infectious Disease Testing Market, by Disease, 2024-2033
8.1.1. Pneumonia Or Streptococcus Associated Infections
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Respiratory Syncytial Virus (RSV)
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. TB and Drug Resistant TB POC
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Influenza/Flu POC
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. HIV POC
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Others
8.1.6.1. Market Revenue and Forecast (2021-2033)
9.1. U.S. Point of Care Infectious Disease Testing Market, by End-user, 2024-2033
9.1.1. Hospitals
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Clinics
9.1.2.1. Market Revenue and Forecast (2021-2033)
9.1.3. Home
9.1.3.1. Market Revenue and Forecast (2021-2033)
9.1.4. Assisted Living Healthcare Facilities
9.1.4.1. Market Revenue and Forecast (2021-2033)
9.1.5. Laboratories
9.1.5.1. Market Revenue and Forecast (2021-2033)
9.1.6. Others
9.1.6.1. Market Revenue and Forecast (2021-2033)
10.1. North America
10.1.1. Market Revenue and Forecast, by Disease (2021-2033)
10.1.2. Market Revenue and Forecast, by End-user (2021-2033)
10.1.3. U.S.
10.1.3.1. Market Revenue and Forecast, by Disease (2021-2033)
10.1.3.2. Market Revenue and Forecast, by End-user (2021-2033)
10.1.4. Rest of North America
10.1.4.1. Market Revenue and Forecast, by Disease (2021-2033)
10.1.4.2. Market Revenue and Forecast, by End-user (2021-2033)
10.2. Europe
10.2.1. Market Revenue and Forecast, by Disease (2021-2033)
10.2.2. Market Revenue and Forecast, by End-user (2021-2033)
10.2.3. UK
10.2.3.1. Market Revenue and Forecast, by Disease (2021-2033)
10.2.3.2. Market Revenue and Forecast, by End-user (2021-2033)
10.2.4. Germany
10.2.4.1. Market Revenue and Forecast, by Disease (2021-2033)
10.2.4.2. Market Revenue and Forecast, by End-user (2021-2033)
10.2.5. France
10.2.5.1. Market Revenue and Forecast, by Disease (2021-2033)
10.2.5.2. Market Revenue and Forecast, by End-user (2021-2033)
10.2.6. Rest of Europe
10.2.6.1. Market Revenue and Forecast, by Disease (2021-2033)
10.2.6.2. Market Revenue and Forecast, by End-user (2021-2033)
10.3. APAC
10.3.1. Market Revenue and Forecast, by Disease (2021-2033)
10.3.2. Market Revenue and Forecast, by End-user (2021-2033)
10.3.3. India
10.3.3.1. Market Revenue and Forecast, by Disease (2021-2033)
10.3.3.2. Market Revenue and Forecast, by End-user (2021-2033)
10.3.4. China
10.3.4.1. Market Revenue and Forecast, by Disease (2021-2033)
10.3.4.2. Market Revenue and Forecast, by End-user (2021-2033)
10.3.5. Japan
10.3.5.1. Market Revenue and Forecast, by Disease (2021-2033)
10.3.5.2. Market Revenue and Forecast, by End-user (2021-2033)
10.3.6. Rest of APAC
10.3.6.1. Market Revenue and Forecast, by Disease (2021-2033)
10.3.6.2. Market Revenue and Forecast, by End-user (2021-2033)
10.4. MEA
10.4.1. Market Revenue and Forecast, by Disease (2021-2033)
10.4.2. Market Revenue and Forecast, by End-user (2021-2033)
10.4.3. GCC
10.4.3.1. Market Revenue and Forecast, by Disease (2021-2033)
10.4.3.2. Market Revenue and Forecast, by End-user (2021-2033)
10.4.4. North Africa
10.4.4.1. Market Revenue and Forecast, by Disease (2021-2033)
10.4.4.2. Market Revenue and Forecast, by End-user (2021-2033)
10.4.5. South Africa
10.4.5.1. Market Revenue and Forecast, by Disease (2021-2033)
10.4.5.2. Market Revenue and Forecast, by End-user (2021-2033)
10.4.6. Rest of MEA
10.4.6.1. Market Revenue and Forecast, by Disease (2021-2033)
10.4.6.2. Market Revenue and Forecast, by End-user (2021-2033)
10.5. Latin America
10.5.1. Market Revenue and Forecast, by Disease (2021-2033)
10.5.2. Market Revenue and Forecast, by End-user (2021-2033)
10.5.3. Brazil
10.5.3.1. Market Revenue and Forecast, by Disease (2021-2033)
10.5.3.2. Market Revenue and Forecast, by End-user (2021-2033)
10.5.4. Rest of LATAM
10.5.4.1. Market Revenue and Forecast, by Disease (2021-2033)
10.5.4.2. Market Revenue and Forecast, by End-user (2021-2033)
11.1. Beckton Dickinson
11.1.1. Company Overview
11.1.2. Product Offerings
11.1.3. Financial Performance
11.1.4. Recent Initiatives
11.2. Roche
11.2.1. Company Overview
11.2.2. Product Offerings
11.2.3. Financial Performance
11.2.4. Recent Initiatives
11.3. Biomerieux
11.3.1. Company Overview
11.3.2. Product Offerings
11.3.3. Financial Performance
11.3.4. Recent Initiatives
11.4. Siemens
11.4.1. Company Overview
11.4.2. Product Offerings
11.4.3. Financial Performance
11.4.4. Recent Initiatives
11.5. Bio-rad
11.5.1. Company Overview
11.5.2. Product Offerings
11.5.3. Financial Performance
11.5.4. Recent Initiatives
11.6. Chembio Diagnostic Systems
11.6.1. Company Overview
11.6.2. Product Offerings
11.6.3. Financial Performance
11.6.4. Recent Initiatives
11.7. Quidel Corporation
11.7.1. Company Overview
11.7.2. Product Offerings
11.7.3. Financial Performance
11.7.4. Recent Initiatives
11.8. Abbott
11.8.1. Company Overview
11.8.2. Product Offerings
11.8.3. Financial Performance
11.8.4. Recent Initiatives
12.1. Primary Research
12.2. Secondary Research
12.3. Assumptions
13.1. About Us
13.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample